Previous studies have raised concerns about the possible increased risks of early stent thrombosis and target lesion revascularisation with the Endeavor® Sprint zotarolimus-eluting stent (ZES; Medtronic, Minneapolis, MN, USA) when compared with the CYPHER Select® Plus sirolimus-eluting stent (SES; Cordis, Johnson & Johnson, Warren, NJ, USA)1,2. As these differences appeared to diminish over time, a potential reversal of their safety profiles with prolonged follow-up was suggested1,2. The purpose of this study was to examine 10-year outcomes in patients who received ZES versus SES in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com